Virologic and Immunologic Response, Clinical Progression, and Highly Active Antiretroviral Therapy Adherence
- 1 December 2002
- journal article
- review article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 31, S112-S117
- https://doi.org/10.1097/00126334-200212153-00005
Abstract
A growing body of evidence suggests that a high degree of adherence is required to achieve and maintain a successful virologic response both in the short and long term. This holds true despite the definition of adherence or how it is measured. Reported differences in the degree of adherence required are likely due to differences in study design, difficulty measuring patient adherence, patient population studied, and the antiretroviral regimen studied. Virologic suppression and immunologic response often go hand in hand, but the impact of adherence on change in CD4 count tends to be delayed and, therefore, less apparent than the impact on HIV viral load. Degree of adherence has also been shown to be associated with AIDS-related morbidity, mortality, and hospitalizations.Keywords
This publication has 29 references indexed in Scilit:
- Correlation between self-reported adherence to highly active antiretroviral therapy (HAART) and virologic outcomeAdvances in Therapy, 2001
- Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV InfectionAnnals of Internal Medicine, 2000
- Predictors of Self-Reported Adherence and Plasma HIV Concentrations in Patients on Multidrug Antiretroviral RegimensJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Adherence to Triple Therapy and Viral Load ResponseJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug ReactionsAnnals of Internal Medicine, 1999
- The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic responseAIDS, 1999
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- A Randomized, Double-blind Trial Comparing Combinations of Nevirapine, Didanosine, and Zidovudine for HIV-Infected PatientsJAMA, 1998
- Randomised placebo-controlled trial of ritonavir in advanced HIV-1 diseaseThe Lancet, 1998
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997